Search for a prescription weight-care provider and the results present a wall of visually identical trust signals. Badges, seals, phrases about licensed clinicians, references to accredited pharmacies. Some of these correspond to verifiable third-party status. Others are graphics.
Distinguishing between them has become a practical skill rather than a specialist one, and the regulatory changes of 2025 made it more consequential than it was during the shortage years. This is an attempt to set out what each credential in this category actually certifies, what it does not, and how a person can check it in a few minutes.
The four things worth verifying
The prescriber’s state licence
A clinician must hold a licence in the state where the patient is located, not merely somewhere. This is the credential that most directly determines whether a prescription is lawful, and it is publicly verifiable.
Every state medical board maintains a searchable licence register. A patient can enter a clinician’s name and see licence status, issue date, speciality and any disciplinary history. The practical obstacle is that many telehealth providers do not identify the reviewing clinician before an intake is complete, which makes verification difficult at the point it would be most useful. A provider that names its clinicians, or at minimum states clearly which licensure applies, has made itself checkable. One that refers only to a network of licensed providers has not.
The pharmacy’s licence and registration type
The pharmacy that prepares and dispenses the medication is a separate entity from the telehealth service, and it carries its own licensure. State boards of pharmacy maintain registers in the same way medical boards do.
The registration type matters considerably in this category. A 503A pharmacy compounds for individual patients against specific prescriptions. A 503B outsourcing facility registers with the FDA and may produce larger volumes without patient-specific prescriptions, but only from substances on the FDA’s 503B Bulks List. These are different regimes with different oversight, and a provider should be able to say which applies to the medication it supplies.
Voluntary accreditation
Beyond mandatory licensure, pharmacies may seek accreditation from independent bodies that assess practice against published standards. Accreditation is voluntary, costs money and takes time, which is what makes it informative. It is a signal of investment in process rather than a legal requirement.
It is also frequently misrepresented. Accreditation applies to a specific facility for a specific period, and an accreditation body’s register is the authoritative source. The badge on a website is not. Checking the register rather than trusting the graphic takes a minute and occasionally produces surprises.
LegitScript or equivalent certification of the online operation
Separate from the pharmacy, the online operation itself can be certified. Certification programmes of this kind assess whether an internet-facing healthcare business meets defined standards, and major advertising and payment platforms require this certification before they will transact with a business in this category. That dependency is what gives it force: losing it has immediate commercial consequences, so maintaining it is not optional for a serious operator.
Why the regulatory shift raised the stakes
The supply environment changed in 2025. The FDA removed tirzepatide from its shortage list in December 2024 and declared the semaglutide injection shortage resolved in February 2025, closing the broad enforcement discretion that had allowed large-scale compounding of both molecules.
Compounding remains lawful. A licensed 503A pharmacy can still prepare these molecules for a specific patient under a valid prescription, but because the FDA no longer treats them as in shortage, doing so requires a prescriber-documented, patient-specific clinical reason. Compounded medications are prepared by a licensed pharmacy for an individual patient, are not approved by the FDA, and do not go through its premarket review for safety, effectiveness or quality. In April 2026 the FDA proposed permanently excluding semaglutide, tirzepatide and liraglutide from the 503B Bulks List, with a comment period extended into July 2026.
During the shortage, every provider had the same answer to how they could supply these medications. That is no longer true, and the differences between providers’ answers now carry information that they previously did not.
How it works in practice
The practical test of a provider is whether the things a patient would want to verify are stated rather than implied.
HealSend, a US telehealth service, states that every patient is reviewed by a US-licensed physician before any prescription is written and that eligibility for GLP-1 medications is determined by that physician. Treatment is open to adults aged 18 to 75 and is not for use during pregnancy. The service operates across most, though not all, US states, which is a licensure consequence rather than a commercial choice and is disclosed as such.
Commercial terms are published rather than quoted after intake: compounded semaglutide at 299 dollars per month and compounded tirzepatide at 399 dollars per month, each as a once-weekly injection, shipped via FedEx in discreet, temperature-controlled packaging with shipping included. Plans are stated to be HSA and FSA eligible for reimbursement. Patients considering whether to buy tirzepatide online can read the clinical review commitment, the state coverage position and the price before starting rather than discovering them during checkout. The company states that if its provider determines a GLP-1 medication is not right for a patient, the patient receives a full refund.
The refund position functions as a credential of a different kind. A provider that returns money when a clinician declines has structured its economics so that a declined prescription is survivable, which is the arrangement that makes a genuine clinical gate possible.
What each credential does not cover
Verification is more useful when its limits are understood, because each of these credentials certifies something narrower than patients tend to assume.
A state medical licence confirms that a clinician met education and examination requirements and remains in good standing. It says nothing about whether that clinician has particular experience in metabolic medicine, and nothing about how much time they spend on an individual review. A licensed physician reviewing an intake carefully and one reviewing it in seconds hold the same credential.
A pharmacy licence confirms that a facility is authorised to operate and is subject to inspection. Inspection frequency and depth vary by state, and a current licence reflects compliance at the last assessment rather than continuous assurance.
Accreditation assesses process and documentation against published standards. It is a meaningful signal of operational investment and it is not a product-quality test. An accredited facility has demonstrated that it has systems; it has not demonstrated that any particular preparation meets a specification.
Certification of an online operation addresses the legitimacy of the business and its compliance posture. It does not evaluate clinical quality or the appropriateness of any individual prescribing decision.
The gap these leave
Taken together, these credentials establish that the entities involved are who they claim to be and are permitted to do what they are doing. That is genuinely valuable and it is a floor rather than a ceiling.
What no public register captures is the thing patients most want to know: whether the clinical judgement applied to their case was sound. That cannot be verified in advance by anyone, which is why the structural signals, whether a prescriber can decline and whether the business survives a declined prescription, carry as much weight as the credentials themselves.
Signals that warrant a second look
No realistic path to a declined prescription
If an intake appears designed so that every submission results in an approval, the clinical review is decorative. Under the current framework the patient-specific determination is the legal foundation, so a gate that never closes is a structural problem rather than a stylistic one.
Unwillingness to name the pharmacy
A provider should be able to identify the dispensing pharmacy and its registration type. Treating that as proprietary is difficult to justify, since it is the information that allows a patient to check licensure independently.
Prices well outside the range
Industry pricing surveys in 2026 put compounded semaglutide around a median in the low hundreds per month. A figure dramatically below the market is not automatically improper, but it is a prompt to establish what has been removed to achieve it.
Badges that do not resolve
Accreditation and certification marks should be checkable in the issuing body’s public register. A mark that does not appear there, or that applies to a different entity than the one supplying the medication, is not the assurance it appears to be.
A workable approach
None of this requires expertise. It requires treating four specific claims as checkable: the prescriber’s state licence, the pharmacy’s licence and registration type, any accreditation, and certification of the online operation. Each has a public register. Each takes a few minutes.
The deeper point is that verification is a different activity from reassurance. Websites in this category are designed to produce reassurance efficiently. Verification has to be done elsewhere, against sources the provider does not control, and the small number of patients who do it are the ones least likely to end up somewhere they would not have chosen knowingly.
